Menu
Search
|

Menu

Close
X

Nabriva Therapeutics PLC NBRV.OQ (NASDAQ Stock Exchange Global Select Market)

1.93 USD
-0.02 (-1.03%)
As of Nov 21
chart
Previous Close 1.95
Open 1.93
Volume 34,815
3m Avg Volume 104,484
Today’s High 2.01
Today’s Low 1.90
52 Week High 6.94
52 Week Low 1.84
Shares Outstanding (mil) 36.63
Market Capitalization (mil) 304.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
5
FY16
4
FY15
4
EPS (USD)
FY18
-1.704
FY17
-7.529
FY16
-7.649
FY15
-35.807
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.60
Price to Sales (TTM)
vs sector
50.61
5.69
Price to Book (MRQ)
vs sector
0.46
5.11
Price to Cash Flow (TTM)
vs sector
--
23.53
Total Debt to Equity (MRQ)
vs sector
0.44
15.71
LT Debt to Equity (MRQ)
vs sector
0.44
11.53
Return on Investment (TTM)
vs sector
-87.80
15.05
Return on Equity (TTM)
vs sector
-88.10
16.62

EXECUTIVE LEADERSHIP

Daniel Burgess
Independent Chairman of the Supervisory Board, Since 2016
Salary: --
Bonus: --
Steven Gelone
President, Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Theodore Schroeder
Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Gary Sender
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
William Sargent
Vice President - Commercial Strategy and Investor Relations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

56 Fitzwilliam Square
DUBLIN     2

Phone:

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.

SPONSORED STORIES